Herbion Apple Cider Vinegar Gummies Asmr Unboxing Healthy Supplement Supplements Asmrvideo

Taking Weight Loss Injections Semaglutide Hims

These are our housemade barbacoa tacos. Delicious, easy, and inexpensive! Made with slow cooked chuck steak, dried chilies, oregano, salt, and pepper.

Shilpa Shetty John Abraham Halthi Breakfast For Weight Loss Weightlosssshare Viral Reels

Lose 20-30 lbs, build lean muscle, and develop a healthy lifestyle without restrictive dieting: https://ransomedbodies.typeform.com/to/amHy3DRf Here is your weight loss shopping guide for Costco in 2025. I have built a list of the best things to buy at Costco and explain why they are great for losing weight and building muscle. If you found this helpful, subscribe for more videos & content like this: https://www.youtube.com/@trizzlemanfitness

Keto Gummies Shark Tank On Amazon Official Website 2024

JOIN MY CLUB

Herbion Apple Cider Vinegar Gummies Asmr Unboxing Healthy Supplement Supplements Asmrvideo

Unboxing With A Pharmacist Unboxing Unboxingvideo Weightloss Diabetes Pharmacist

Work with JJ at http://www.jjbirden.co Discover the top GLP-1 medication nutritional system in this video. Learn how this system can benefit your health and wellness goals using a GLP-1 medication or weight loss program.

Thanksgiving Day On Keto Diet Cheat Days On Keto

Key Takeaways from GLP-1 Medication Journey Part 4 #uk #zepbound #obese #obesity #diet #wegovy

Study Finds That People Using Weight Loss Drugs Can Help Reduce Tobacco Dependence

Boost your energy with apple cider vinegar gummies! #applecidervinegargummies #energy #fok

People S Keto Gummies Uk

**GLP-1 News | May 5 — WHO Backs GLP-1s, Lilly Hits \$6B, CVS Picks Wegovy, and More** Welcome to *The Downsized News*, your trusted source for real updates, honest analysis, and patient-first reporting about GLP-1 medications like Zepbound, Mounjaro, Wegovy, Ozempic, and semaglutide. In this episode, Christopher and Laraine Durham—who’ve lost more than 150 pounds combined using GLP-1s—bring you the latest headlines and why they matter for real people using these medications to treat the disease of obesity. Here’s what we’re covering this week: * **The World Health Organization (WHO)** is officially backing GLP-1s for the treatment of obesity in adults. This is a major turning point—but they also warn that cost and access remain global barriers. We break down what this could mean for the future of coverage and generics. * **CVS Caremark’s Big Move**: Starting July 1, Wegovy becomes the preferred GLP-1 on CVS Caremark’s formularies. That could create new access for some—and new roadblocks for others using Zepbound or Mounjaro. We explain how PBMs work and what this decision really means for patients. * **Eli Lilly’s Q1 2025 Earnings**: Lilly just posted over \$6 billion in GLP-1 sales. Zepbound and Mounjaro are dominating the market—and their oral GLP-1 pill, orforglipron, is showing promising results in trials. We discuss the financials, the future pipeline, and what it means for self-pay patients. * **Novo Nordisk & Telehealth Twist**: In a surprising turn, Novo Nordisk has partnered with Hims & Hers, Ro, and LifeMD—platforms they previously warned against. We explore why they made the deal, how the shortage ruling changed everything, and what this means for access and control. * **Research into GLP-1 Effectiveness**: Illumina and Ovation.io are launching the largest-ever study to understand why some people respond to GLP-1s—and others don’t. This kind of research could unlock personalized obesity treatment in the future. * **GLP-1s and Heart Health**: The American Heart Association is funding seven studies to explore how these medications reduce cardiovascular risk, and why not everyone sees the same benefits. It’s a big step toward more tailored care for people with obesity. * **GLP-1s and Liver Disease**: New clinical trial results show semaglutide could help patients with MASH, a serious liver disease tied to obesity. Wegovy is now under FDA review for this indication. * **Oral Semaglutide for Obesity**: The FDA has accepted Novo Nordisk’s application for a once-daily oral version of Wegovy. A decision is expected in late 2025, and it could be a game-changer for people looking for a non-injectable option. At *The Downsized*, we’re not doctors—we’re patients sharing our experience and the latest information to help you stay informed on your GLP-1 adventure. Always talk to your healthcare provider before starting or changing your treatment. DOWNSIZED WEBSITE: https://thedownsized.org/ DOWNSIZED GLP-1 COMPANION PRODUCT STORE: https://thedownsized.org/downsized-store JOIN CLUB DOWNSIZED: @thedownsized FOR SPONSORSHIPS, BRAND DEALS & COLLABS: https://thedownsized.org/contact/ 00:00 Lilly's $6 Billion GLP-1 Bombshell—and What Comes Next 01:23 WHO Endorses GLP-1s for Obesity 07:56 Eli Lilly's Blockbuster Quarter and Future Innovations 12:21 Novo Nordisk Partners with Telehealth Companies 15:21 Research into GLP-1 Effectiveness 19:20 American Heart Association's GLP-1 Research Grants 23:38 Semaglutide's Potential for Treating Liver Disease 28:08 Conclusion and Wrap-Up